Page 82 - GPD-3-3

Gene & Protein in Disease Gene therapy progress for DEB

99. Heinonen S, Mannikko M, Klement JF, doi: 10.30802/AALAS-CM-21-000063
Whitaker-Menezes D, Murphy GF, Uitto J. Targeted
inactivation of the type VII collagen gene (Col7a1) in 102. Nyström A, Velati D, Mittapalli VR, Fritsch A, Kern JS,
mice results in severe blistering phenotype: A model for Bruckner-Tuderman L. Collagen VII plays a dual role in
recessive dystrophic epidermolysis bullosa. J Cell Sci. wound healing. J Clin Invest. 2013;123(8):3498-3509.
1999;112(21):3641-3648. doi: 10.1172/JCI68127
doi: 10.1242/jcs.112.21.3641 103. Smith BRC, Nyström A, Nowell CJ, et al. Mouse models
100. Fritsch A, Loeckermann S, Kern JS, et al. A hypomorphic for dominant dystrophic epidermolysis bullosa carrying
mouse model of dystrophic epidermolysis bullosa reveals common human point mutations recapitulate the human
mechanisms of disease and response to fibroblast therapy. disease. Dis Model Mech. 2021;14(6):dmm048082.
J Clin Invest. 2008;118(5):1669-1679.
doi: 10.1242/dmm.048082
doi: 10.1172/JCI34292
104. Takaki S, Shimbo T, Ikegami K, et al. Generation of a
101. Chen VM, Southwell K, Huynh E, Gavett S, Richey L, recessive dystrophic epidermolysis bullosa mouse model
Esmail M. Corneal changes and strategies to improve with patient-derived compound heterozygous mutations.
survival of hypomorphic collagen VII-deficient mice for Lab Invest. 2022;102(6):574-580.
the study of ocular dystrophic epidermolysis bullosa. Comp
Med. 2022;72(1):14-21. doi: 10.1038/s41374-022-00735-5

Volume 3 Issue 3 (2024) 13 doi: 10.36922/gpd.4047